Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
idiopathic pulmonary fibrosis
Biotech
Boehringer's phase 3 lung fibrosis trial hits primary endpoint
Boehringer has ended a decade of industrywide failures in idiopathic pulmonary fibrosis with a phase 3 win for a potentially first-in-class drug.
Nick Paul Taylor
Sep 16, 2024 8:30am
Endeavor links IPF drug to improved lung function in phase 2
May 20, 2024 5:55am
Vicore's IPF drug improves lung function in phase 2 win
May 20, 2024 2:00am
Fibrosis-focused Endeavor bags $132.5M series C
Apr 24, 2024 7:30am
Surrozen's Wnt mimetic antibody works in mice with lung fibrosis
Apr 4, 2024 4:30am
J&J-allied bio files IPO to take fight to BMS, Roche and more
Mar 18, 2024 7:15am
